BioSpace News Archive

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended June 30, 2021, and other recent developments.

Orthopaedic spine surgeon, Dr. Mark W. McFarland performed the first Kyphoplasty using the Stryker SpineJack® System in the Hampton Roads region of Virginia, on Monday, August 2, 2021.

Tryp has also entered into an agreement with Gad Consulting Services to collaborate on the preclinical studies

Artificial bone is a bone-like material that is artificially created in the laboratory to be used in bone grafts.

Cone Beam Computed Tomography is a medical imaging procedure where the resultant X-rays are divergent and form cone-like structures.

AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces that it will present “Drug Reimbursement Strategies for 21st Century Cures” at the IDN and Bio/Pharma Partnering Summit, Aug. 19, 11:15 a.m.–12 p.m. EDT.

Ebola vaccine is a procedure of elimination or killing of microorganisms in or about the dental equipment.

Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an ongoing research collaboration to broaden patient participation in Adaptive’s clinical studies.

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, announced financial results for its first fiscal quarter ended June 30, 2021.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for second quarter ended June 30, 2021.